

Kelvin K Chan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3593228/kelvin-k-chan-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187
papers

1,693
citations

23
h-index

34
g-index

202
ext. papers

2,313
ext. citations

3.8
avg, IF

5.08
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 187 | Chemotherapy-induced cardiotoxicity: detection, prevention, and management. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 869-78 | 3.8 | 75 |
| 186 | Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013 , 1, E1-8 | 2.5 | 71 |
| 185 | Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E820-6 | 4.2 | 63 |
| 184 | The economic burden of cancer care in Canada: a population-based cost study. <i>CMAJ Open</i> , 2018 , 6, E1-E10 | 1.9 | 55 |
| 183 | Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1570-9 | 7.5 | 50 |
| 182 | The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. <i>Journal of the National Cancer Institute</i> , 2016 , 108, | 9.7 | 48 |
| 181 | Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182 | 7.5 | 46 |
| 180 | A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 113-120 | 3.8 | 46 |
| 179 | Phase-specific and lifetime costs of cancer care in Ontario, Canada. <i>BMC Cancer</i> , 2016 , 16, 809 | 4.8 | 45 |
| 178 | Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2764-2771 | 2.2 | 44 |
| 177 | Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. <i>Journal of Oncology Practice</i> , 2018 , 14, e280-e294 | 3.1 | 44 |
| 176 | Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. <i>International Journal of Cardiology</i> , 2018 , 261, 228-233 | 3.2 | 40 |
| 175 | Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. <i>International Journal of Cancer</i> , 2018 , 143, 430-437 | 7.5 | 38 |
| 174 | Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013 , 1, E151-8 | 2.5 | 35 |
| 173 | Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. <i>Cancer Medicine</i> , 2020 , 9, 160-169 | 4.8 | 34 |
| 172 | Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018 , 74, 57-62 | 10.2 | 33 |
| 171 | Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience. <i>Cancer</i> , 2016 , 122, 893-8 | 6.4 | 32 |

| | | | |
|-----|---|-----|----|
| 170 | Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017 , 19, 44 | 6.9 | 31 |
| 169 | A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. <i>PLoS ONE</i> , 2014 , 9, e108749 | 3.7 | 27 |
| 168 | Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. <i>Journal of Oncology Practice</i> , 2016 , 12, e369-79 | 3.1 | 27 |
| 167 | Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study. <i>Research Synthesis Methods</i> , 2019 , 10, 465-475 | 7.2 | 25 |
| 166 | Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1064-71 | 2.2 | 25 |
| 165 | Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies. <i>Medical Decision Making</i> , 2014 , 34, 863-72 | 2.5 | 23 |
| 164 | Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions. <i>Journal of Oncology Practice</i> , 2017 , 13, e421-e430 | 3.1 | 22 |
| 163 | Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 71-79 | 3.9 | 22 |
| 162 | Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017 , 22, 694-699 | 5.7 | 19 |
| 161 | Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. <i>BMJ Open</i> , 2020 , 10, e032884 | 3 | 18 |
| 160 | Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e710-23 | 3.1 | 17 |
| 159 | Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. <i>The Cochrane Library</i> , 2015 , CD010341 | 5.2 | 17 |
| 158 | Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017 , 12, 95-108 | 1.1 | 17 |
| 157 | Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. <i>Cancer</i> , 2015 , 121, 2637-45 | 6.4 | 16 |
| 156 | The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021 , 23, 894-904 | 1 | 16 |
| 155 | Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. <i>PLoS ONE</i> , 2017 , 12, e0185198 | 3.7 | 15 |
| 154 | Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. <i>Clinical Lung Cancer</i> , 2017 , 18, 345-353.e5 | 4.9 | 14 |
| 153 | Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018 , 40, 2029-2042 | 4.2 | 14 |

| | | | |
|-----|--|------|----|
| 152 | Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 145, 102817 | 7 | 14 |
| 151 | Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. <i>Lancet Haematology</i> , 2020 , 7, e146-e156 | 14.6 | 12 |
| 150 | Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. <i>Cancer Medicine</i> , 2017 , 6, 2017-2033 | 4.8 | 12 |
| 149 | Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. <i>Cancer</i> , 2020 , 126, 1717-1726 | 6.4 | 12 |
| 148 | Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 535-44 | 4.4 | 12 |
| 147 | Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. <i>Value in Health</i> , 2017 , 20, 586-592 | 3.3 | 11 |
| 146 | Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019 , 8, 1584-1593 | 4.8 | 11 |
| 145 | Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies. <i>Journal of Oncology Practice</i> , 2017 , 13, e646-e652 | 3.1 | 11 |
| 144 | A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 646-654 | 7.6 | 11 |
| 143 | Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. <i>Cancer Medicine</i> , 2018 , 7, 2816 | 4.8 | 11 |
| 142 | Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer. <i>Breast Journal</i> , 2015 , 21, 658-64 | 1.2 | 10 |
| 141 | Metastasis to gastrostomy sites from upper aerodigestive tract malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2020 , 91, 1005-1014.e17 | 5.2 | 10 |
| 140 | Peri-Infarct Quantification by Cardiac Magnetic Resonance to Predict Outcomes in Ischemic Cardiomyopathy: Prognostic Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e009156 | 3.9 | 10 |
| 139 | Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 675-684 | 2.2 | 10 |
| 138 | Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. <i>Cancer</i> , 2018 , 124, 1269-1278 | 6.4 | 10 |
| 137 | Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments. <i>Medical Decision Making</i> , 2017 , 37, 262-272 | 2.5 | 9 |
| 136 | Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials. <i>JAMA Oncology</i> , 2019 , 5, 1188-1194 | 13.4 | 9 |
| 135 | Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019 , 39, 370-378 | 2.5 | 9 |

| | | | |
|-----|--|------|---|
| 134 | Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 169-80 | 4.4 | 9 |
| 133 | Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016. <i>Cancer Medicine</i> , 2020 , 9, 3407-3416 | 4.8 | 9 |
| 132 | Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach. <i>Medical Decision Making</i> , 2016 , 36, 223-33 | 2.5 | 9 |
| 131 | Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale. <i>JAMA Network Open</i> , 2019 , 2, e196803 | 10.4 | 9 |
| 130 | Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1428-9 | 2.2 | 9 |
| 129 | Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. <i>CMAJ Open</i> , 2016 , 4, E66-72 | 2.5 | 9 |
| 128 | Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review. <i>JAMA Network Open</i> , 2021 , 4, e2033004 | 10.4 | 9 |
| 127 | Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 155-165 | 4.4 | 8 |
| 126 | Less than ideal: how oncologists practice with limited drug access. <i>Journal of Oncology Practice</i> , 2012 , 8, 190-5 | 3.1 | 8 |
| 125 | Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?. <i>Cancer Medicine</i> , 2020 , 9, 215-224 | 4.8 | 8 |
| 124 | Economic evaluation of smoking cessation in Ontario's regional cancer programs. <i>Cancer Medicine</i> , 2018 , 7, 4765-4772 | 4.8 | 8 |
| 123 | A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)?. <i>Oral Oncology</i> , 2017 , 71, 1-10 | 4.4 | 7 |
| 122 | Nonsurgical management of resectable oral cavity cancer in the wake of COVID-19: A rapid review and meta-analysis. <i>Oral Oncology</i> , 2020 , 109, 104849 | 4.4 | 7 |
| 121 | A Systematic Approach for the Simultaneous Assay of Some Antituberculous Drugs in CSF and Plasma by Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1988 , 11, 1051-1073 | | 7 |
| 120 | Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, e201-e210 | 2.3 | 7 |
| 119 | Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020 , 126, 1530-1540 | 6.1 | 7 |
| 118 | Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 217-227 | 4.4 | 7 |
| 117 | Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada. <i>BMC Cancer</i> , 2020 , 20, 304 | 4.8 | 7 |

| | | | |
|-----|--|-----|---|
| 116 | Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. <i>BMC Cancer</i> , 2018 , 18, 694 | 4.8 | 7 |
| 115 | The impact of cancer drug wastage on economic evaluations. <i>Cancer</i> , 2017 , 123, 3583-3590 | 6.4 | 6 |
| 114 | Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life. <i>Supportive Care in Cancer</i> , 2021 , 29, 515-524 | 3.9 | 6 |
| 113 | Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis. <i>Radiotherapy and Oncology</i> , 2018 , 129, 435-440 | 5.3 | 6 |
| 112 | Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 137-145 | 4.4 | 5 |
| 111 | The impact of pricing strategy on the costs of oral anti-cancer drugs. <i>Cancer Medicine</i> , 2019 , 8, 3770-3781 | 4.8 | 5 |
| 110 | Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6041-6041 | 2.2 | 5 |
| 109 | A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0140187 | 3.7 | 5 |
| 108 | Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 278-285 | 7.3 | 5 |
| 107 | Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life. <i>Psycho-Oncology</i> , 2021 , 30, 103-110 | 3.9 | 5 |
| 106 | Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. <i>International Journal of Cancer</i> , 2017 , 140, 2162-2167 | 7.5 | 4 |
| 105 | Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>Radiation Oncology</i> , 2015 , 10, 95 | 4.2 | 4 |
| 104 | The Theoretical Relationship between Sample Size and Expected Predictive Precision for EQ-5D Valuation Studies: A Mathematical Exploration and Simulation Study. <i>Medical Decision Making</i> , 2020 , 40, 339-347 | 2.5 | 4 |
| 103 | Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102971 | 7 | 4 |
| 102 | A Cost-Utility Analysis of Magnetic Resonance (MR) Guided Brachytherapy Versus Two-Dimensional and Computed Tomography (CT) Guided Brachytherapy for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 107, 512-521 | 4 | 4 |
| 101 | Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. <i>Human Reproduction</i> , 2020 , 35, 434-445 | 5.7 | 4 |
| 100 | Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. <i>ESMO Open</i> , 2016 , 1, e000124 | 6 | 4 |
| 99 | Predictors of surgical readmission, unplanned hospitalization and emergency department use in head and neck oncology: A systematic review. <i>Oral Oncology</i> , 2020 , 111, 105039 | 4.4 | 4 |

| | | | |
|----|---|-----|---|
| 98 | Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky050 | 4.6 | 4 |
| 97 | Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. <i>Heart</i> , 2019 , 105, 1649-1655 | 5.1 | 3 |
| 96 | The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 81-100 | 2.2 | 3 |
| 95 | Serious adverse events among a population-based cohort of patients receiving first-line chemotherapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14003-e14003 ³ | 2.2 | 3 |
| 94 | Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9087-9087 | 2.2 | 3 |
| 93 | Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1489-1496 | 7.3 | 3 |
| 92 | Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives. <i>CMAJ Open</i> , 2020 , 8, E772-E778 | 2.5 | 3 |
| 91 | Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. <i>Current Oncology</i> , 2021 , 28, 4174-4183 | 2.8 | 3 |
| 90 | The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020 , 9, 7072-7082 | 4.8 | 3 |
| 89 | The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patients. <i>International Journal of Cancer</i> , 2021 , 149, 1031-1043 | 7.5 | 3 |
| 88 | Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1399-1408 | 1.9 | 3 |
| 87 | Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score-Matched Cohort Study. <i>JCO Oncology Practice</i> , 2021 , OP2100299 | 2.3 | 3 |
| 86 | The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1132-1137 | 3.6 | 2 |
| 85 | Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. <i>Medical Decision Making</i> , 2018 , 38, 26-33 | 2.5 | 2 |
| 84 | ASCO Provisional Clinical Opinion for Hepatitis B Virus Screening Before Cancer Therapy: Are These the Right Tests in the Right Patients?. <i>Journal of Oncology Practice</i> , 2015 , 11, e490-4 | 3.1 | 2 |
| 83 | Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9504-9504 | 2.2 | 2 |
| 82 | Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 375-375 | 2.2 | 2 |
| 81 | A phase I study of MR-HIFU hyperthermia (HT) with radiation (RT) and chemotherapy (CT) for recurrent rectal cancer. 2019 , 5, 78-78 | | 2 |

| | | | |
|----|---|------|---|
| 80 | The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2133388 | 10.4 | 2 |
| 79 | Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival.. <i>Value in Health</i> , 2022 , 25, 622-629 | 3.3 | 2 |
| 78 | Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.. <i>Current Oncology</i> , 2021 , 28, 4645-4654 | 2.8 | 2 |
| 77 | High-Cost Patients and Preventable Spending: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 23-31 | 7.3 | 2 |
| 76 | Health technology assessment methodology in metastatic renal cell carcinoma. <i>Nature Reviews Urology</i> , 2020 , 17, 3-5 | 5.5 | 2 |
| 75 | Value-based pricing: Toward achieving a balance between individual and population gains in health benefits. <i>Cancer Medicine</i> , 2020 , 9, 94-103 | 4.8 | 2 |
| 74 | Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups. <i>Value in Health</i> , 2020 , 23, 1157-1162 | 3.3 | 2 |
| 73 | Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021 , 22, 723-733 | 3.6 | 2 |
| 72 | Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada. <i>International Journal of Cancer</i> , 2021 , 148, 1910-1918 | 7.5 | 2 |
| 71 | Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021 , 6, 23814683211021060 | 1.5 | 2 |
| 70 | End-of-life outcomes with or without early palliative care: a propensity score matched, population-based cancer cohort study. <i>BMJ Open</i> , 2021 , 11, e041432 | 3 | 2 |
| 69 | Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis. <i>Age and Ageing</i> , 2018 , 47, 654-660 | 3 | 2 |
| 68 | Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.. <i>JAMA Oncology</i> , 2022 , | 13.4 | 2 |
| 67 | Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e2145460 | 10.4 | 2 |
| 66 | Impact of cancer surgery slowdowns on patient survival during the COVID-19 pandemic: a microsimulation modelling study.. <i>Cmaj</i> , 2022 , 194, E408-E414 | 3.5 | 2 |
| 65 | Evaluation of the impact of patient involvement in health technology assessments: A scoping review. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 217-223 | 1.8 | 1 |
| 64 | Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?. <i>European Journal of Cancer</i> , 2016 , 56, 186-187 | 7.5 | 1 |
| 63 | ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis. <i>Blood</i> , 2016 , 128, 1183-1183 | 2.2 | 1 |

| | | | |
|----|---|-----|---|
| 62 | Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e16558-e16558 | 2.2 | 1 |
| 61 | Burnout among Canadian oncologists and oncology residents.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6549-6549 | 2.2 | 1 |
| 60 | Do elderly and young patients derive similar relative survival benefits from novel oncology drugs? A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10029-10029 | 2.2 | 1 |
| 59 | Immunotherapy (IO) versus non-IO for oncology drugs: Comparing survival benefits (SB) using restricted mean survival time.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6617-6617 | 2.2 | 1 |
| 58 | Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-276 | 2.2 | 1 |
| 57 | A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 247-247 | 2.2 | 1 |
| 56 | Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies. <i>Blood</i> , 2021 , 138, 4011-4011 | 2.2 | 1 |
| 55 | Examining the association between oncology drug clinical benefit and the time to public reimbursement. <i>Cancer Medicine</i> , 2021 , 11, 380 | 4.8 | 1 |
| 54 | A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2021 , | 1.2 | 1 |
| 53 | A network meta-analysis-based cost-effectiveness analysis of systematic therapies in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6611-6611 | 2.2 | 1 |
| 52 | Impact of rarity on Canadian oncology health technology assessment and funding. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 1-6 | 1.8 | 1 |
| 51 | Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care. <i>Current Oncology</i> , 2021 , 28, 1641-1651 | 2.8 | 1 |
| 50 | Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021 , 150, 203-210 | 7.5 | 1 |
| 49 | Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. <i>CMAJ Open</i> , 2019 , 7, E516-E523 | 3.5 | 1 |
| 48 | Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs. <i>Current Oncology</i> , 2021 , 28, 606-618 | 2.8 | 1 |
| 47 | Reply to K. Yokoyama et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2417-2419 | 2.2 | 1 |
| 46 | The Edmonton Symptom Assessment System: A narrative review of a standardized symptom assessment tool in head and neck oncology. <i>Oral Oncology</i> , 2021 , 123, 105595 | 4.4 | 0 |
| 45 | Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021 , 26, 100287 | 2 | 0 |

| | | | |
|----|---|------|---|
| 44 | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021 , 11, e046707 | 3 | o |
| 43 | Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 173, 103660 | 7 | o |
| 42 | Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.. <i>Oral Oncology</i> , 2022 , 130, 105903 | 4.4 | o |
| 41 | Engaging specialist oncologists in the assessment of oncology drugs in Canada. <i>Lancet Oncology, The</i> , 2017 , 18, 573-575 | 21.7 | |
| 40 | Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319852594 | 1.5 | |
| 39 | Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1807-1808 | 13.4 | |
| 38 | Pharmacokinetic contributions to drug use. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1985 , 10, 257-62 | | |
| 37 | Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study. <i>Blood</i> , 2021 , 138, 1969-1969 | 2.2 | |
| 36 | Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 472-472 | 2.2 | |
| 35 | Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 327-327 | 2.2 | |
| 34 | Implementation of an electronic referral smoking cessation tool into clinical practice across cancer clinics of different disease sites and institutions.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 112-112 | 2.2 | |
| 33 | Use of QT interval prolonging drugs (QT drugs) and electrocardiogram (ECG) monitoring in patients (pts) receiving first-line anti-cancer systemic therapy (tx): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6598-6598 | 2.2 | |
| 32 | Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6619-6619 | 2.2 | |
| 31 | Assessing the difference in efficacy and effectiveness of cancer systemic treatment (tx): A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6581-6581 | 2.2 | |
| 30 | A descriptive analysis of clinician input and feedback into the CADTH pan-Canadian Oncology Drug Review process.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 42-42 | 2.2 | |
| 29 | Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 205-205 | 2.2 | |
| 28 | Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies. <i>Blood</i> , 2018 , 132, 4800-4800 | 2.2 | |
| 27 | A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 396-396 | 2.2 | |

| | | |
|----|---|-----|
| 26 | Measuring the long-term fail of curve survival benefits in oncology trials: A comparison of the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2585-2585 | 2.2 |
| 25 | Do the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure Absolute or Relative clinical benefit?. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18378-e18378 | 2.2 |
| 24 | Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1037-1037 ² | 2.2 |
| 23 | A weighted criterion-based approach to value assessment of oncology drugs.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6627-6627 | 2.2 |
| 22 | Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6641-6641 | 2.2 |
| 21 | Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11561-11561 | 2.2 |
| 20 | A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6639-6639 | 2.2 |
| 19 | Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) hyperthermia for primary rectal cancer: A virtual feasibility analysis. 2019 , 5, 77-77 | 2.2 |
| 18 | Pharmacokinetic (PK) assessment of dacomitinib (D) in patients with locoregionally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through gastrostomy feeding tube (GT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17049-e17049 | 2.2 |
| 17 | Associations among socioeconomic status (SES), patterns of care and outcomes in breast cancer (BC) patients (pts) in a universal health care system: Ontario's experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6625-6625 | 2.2 |
| 16 | Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1081-1081 | 2.2 |
| 15 | A Bayesian multiple-treatments meta-analysis of neoadjuvant treatments for locally advanced, resectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4074-4074 | 2.2 |
| 14 | Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6024-6024 | 2.2 |
| 13 | An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus screening.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6627-6627 | 2.2 |
| 12 | HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11-11 | 2.2 |
| 11 | An electronic prompt to improve hepatitis B virus screening prior to cancer treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 169-169 | 2.2 |
| 10 | A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 195-195 | 2.2 |
| 9 | Cardiac care after myocardial infarction in cancer survivors: A population-based study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9578-9578 | 2.2 |

| | | |
|---|---|-----|
| 8 | Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9626-9626 | 2.2 |
| 7 | G-CSF as Secondary Prophylaxis of Febrile Neutropenia In the Management of Advanced-Stage Hodgkin Lymphoma Treated with ABVD Chemotherapy: A Decision Analysis.. <i>Blood</i> , 2010 , 116, 3831-3831 ^{2,2} | |
| 6 | A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14532-e14532 | 2.2 |
| 5 | Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021 , 39, 1075-1084 | 4.4 |
| 4 | Understanding the Feasibility of Implementing CAR T-Cell Therapies from a Canadian Perspective. <i>Healthcare Policy</i> , 2021 , 16, 89-105 | 1.1 |
| 3 | The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. <i>Current Oncology</i> , 2021 , 28, 3649-3658 | 2.8 |
| 2 | Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.. <i>Current Oncology</i> , 2022 , 29, 2046-2063 | 2.8 |
| 1 | Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.. <i>BMC Medical Research Methodology</i> , 2021 , 21, 282 | 4.7 |